Neurosurgery Department, Galilee Medical Center, Naharyia, Israel.
Sagol Center for Hyperbaric Medicine and Research, Assaf Harofeh Medical Center, Zerifin, Israel.
Restor Neurol Neurosci. 2020;38(1):93-107. doi: 10.3233/RNN-190959.
Previous studies have shown that hyperbaric oxygen therapy (HBOT) can improve the motor functions and memory of post-stroke patients in the chronic stage.
The aim of this study is to evaluate the effects of HBOT on overall cognitive functions of post-stroke patients in the chronic stage. The nature, type and location of the stroke were investigated as possible modifiers.
A retrospective analysis was conducted on patients who were treated with HBOT for chronic stroke (>3 months) between 2008-2018. Participants were treated in a multi-place hyperbaric chamber with the following protocols: 40 to 60 daily sessions, 5 days per week, each session included 90 min of 100% oxygen at 2 ATA with 5 min air brakes every 20 minutes. Clinically significant improvements (CSI) were defined as > 0.5 standard deviation (SD).
The study included 162 patients (75.3% males) with a mean age of 60.75±12.91. Of them, 77(47.53%) had cortical strokes, 87(53.7%) strokes were located in the left hemisphere and 121 suffered ischemic strokes (74.6%).HBOT induced a significant increase in all the cognitive function domains (p < 0.05), with 86% of the stroke victims achieving CSI. There were no significant differences post-HBOT of cortical strokes compared to sub-cortical strokes (p > 0.05). Hemorrhagic strokes had a significantly higher improvement in information processing speed post-HBOT (p < 0.05). Left hemisphere strokes had a higher increase in the motor domain (p < 0.05). In all cognitive domains, the baseline cognitive function was a significant predictor of CSI (p < 0.05), while stroke type, location and side were not significant predictors.
HBOT induces significant improvements in all cognitive domains even in the late chronic stage. The selection of post-stroke patients for HBOT should be based on functional analysis and baseline cognitive scores rather than the stroke type, location or side of lesion.
先前的研究表明,高压氧治疗(HBOT)可改善慢性期脑卒中患者的运动功能和记忆力。
本研究旨在评估 HBOT 对慢性期脑卒中患者整体认知功能的影响。研究了脑卒中的性质、类型和部位作为可能的修饰因子。
对 2008 年至 2018 年间接受 HBOT 治疗的慢性脑卒中(>3 个月)患者进行了回顾性分析。参与者在多床位高压舱中接受治疗,方案如下:40-60 个每日疗程,每周 5 天,每个疗程包括 90 分钟 100%氧气,在 2 ATA 下进行,每 20 分钟进行 5 分钟空气制动。临床显著改善(CSI)定义为>0.5 个标准差(SD)。
本研究纳入了 162 名患者(75.3%为男性),平均年龄为 60.75±12.91 岁。其中,77 例(47.53%)为皮质性脑卒中,87 例(53.7%)脑卒中位于左半球,121 例为缺血性脑卒中(74.6%)。HBOT 可显著提高所有认知功能领域的水平(p<0.05),86%的脑卒中患者达到 CSI。HBOT 后皮质性脑卒中与皮质下脑卒中相比无显著差异(p>0.05)。HBOT 后,出血性脑卒中的信息处理速度显著提高(p<0.05)。左半球脑卒中的运动域增加幅度更高(p<0.05)。在所有认知领域,基线认知功能是 CSI 的显著预测因子(p<0.05),而脑卒中类型、部位和侧别则不是显著预测因子。
HBOT 可显著改善慢性期晚期所有认知领域的功能。选择接受 HBOT 的脑卒中患者应基于功能分析和基线认知评分,而不是脑卒中类型、部位或侧别。